Follow the 서린바이오 share price and the full directors' dealings record of the company, a listed issuer based in South Korea. Shares trade on the KR market, under the supervision of DART (FSS). Operating in the Health Care sector, 서린바이오 has published 25 insider filings. Market capitalisation: €36.6bn. The latest transaction was reported on 2 April 2026 (Purchase). Among the most active insiders: 황을문. The full history is accessible without an account.
25
Insider Decl.
n/a
Thresholds
n/a
18 ops.
Buy Volume
n/a
1 ops.
Sell Volume
24Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 19,659 of 29,064 companies
40.2
score / 100
Value
52
Quality
28
FCF yld12%
Earn yld2.0%
EV/EBITDA17.9x
ROE0.5%
Gross mgn22%
Net mgn0.9%
Debt/EBITDA4.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.